Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Nuevos compuestos antirreumáticos con potente actividad antiinflamatoria

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOCZ20150728001
Publicado:
18/07/2016
Caducidad:
25/01/2017
Resumen:
Una institución académica checa ha desarrollado nuevos compuestos con potente actividad antiinflamatoria basados en la inhibición de un nuevo blanco molecular en la artritis reumatoide. Los derivados de pirazolopirimidina inhiben de forma selectiva la quinasa dependiente de ciclina (CDK9), una enzima recientemente descubierta como nueva diana para medicamentos de la artritis reumatoide en neutrófilos. La institución está interesada en establecer acuerdos de licencia o cooperación en materia de investigación y busca socios que ofrezcan asistencia para realizar los ensayos clínicos y lanzar el producto al mercado.


Details

Tittle:
Novel antirheumatics compounds with strong anti-inflammatory activity
Summary:
Czech academic institution developed a novel compounds with strong anti-inflammatory activity based on an exceptionally strong inhibition of a new molecular target in rheumatic arthritis. License agreement or research cooperation agreement is offered. The institution is looking for a partner who will help to develop the product to clinical trial or get the substance to the market.
Description:
The Czech academic institution developed a novel antirheumatics compounds with strong anti-inflammatory a activity. Rheumatic arthritis is the most common autoimmune inflammatory disease with prevalence of about 1%. Rheumatic arthritis is a chronic, systemic, inflammatory disease that primarily affects the joints, but it also has several additional manifestations, most notably an increased incidence of cardiovascular disease. Without effective treatment rheumatic arthritis may result in work disability and premature death. Recent introduction of biologics has widened treatment options, however 1 in 3 patients do not respond to these therapies. Moreover these drugs are very expensive and have to be taken by the patient long term. New drugs with novel mechanisms of action are therefore urgently needed, especially as the incidence of rheumatic arthritis has been increasing with the population ageing.
This academic institution is looking for partners who will help to develop the product to clinical trial or get the substance to the market. The cooperation could be in a form of license agreement or research cooperation agreement.
Advantages and Innovations:
The invention provides a large number of novel substituted pyrazolopyrimidine derivatives with potent anti-inflammatory activity that can be used for treatment of rheumatic arthritis. They selectively inhibit the cyclin-dependent kinase 9 (CDK9), an enzyme that has been recently discovered as a new target for rheumatic arthritis drugs in neutrophils. The compounds induce neutrophil apoptosis, inhibit fMLP-induced superoxide generation and decrease TNFinduced secretion of IL-8 by neutrophils. They also inhibit proliferation of synovial fibroblasts from RA patients. The lead compound reduces cell infiltration, cytokine production both in the circulation and at the inflamed site in the mouse carrageenan air pouch model.
Stage of Development:
Under development/lab tested
IPs:
Secret Know-how,Patent(s) applied for but not yet granted,Exclusive Rights
CommeR Statunts Regarding IPR Status:
The patent in PCT stage and can specify coverage of the patent.

Partner sought

Type and Role of Partner Sought:
The academic institution is looking for a partner (research institution, university, academic institution, company) who will help to develop the product to clinical trial or get the substance to the market.

Client

Type and Size of Client:
R&D Institution
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
Czech
English
German
Spanish

Keywords

Technology Keywords:
06001002 Investigaciones clínicas, ensayos
06001015 Productos farmacéuticos / medicamentos